Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12199796rdf:typepubmed:Citationlld:pubmed
pubmed-article:12199796lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0018956lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0376152lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C1257975lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0018591lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C0332283lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:12199796lifeskim:mentionsumls-concept:C1881865lld:lifeskim
pubmed-article:12199796pubmed:issue4lld:pubmed
pubmed-article:12199796pubmed:dateCreated2002-8-29lld:pubmed
pubmed-article:12199796pubmed:abstractTextA 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood CD34+ haematopoietic stem cells and bone-marrow-derived mesenchymal stem cells (MSC) from her human leucocyte antigen haplotype-mismatched father after myeloablative conditioning therapy. The patient engrafted rapidly and had no acute or chronic graft-versus-host disease. Since transplantation, the patient has shown an enduring trilineage haematological complete response without any evidence of leukaemia relapse at 31 months. We suggest that MSC can be used effectively for genetically haploidentical haematopoietic stem cell transplantation for acute leukaemia.lld:pubmed
pubmed-article:12199796pubmed:languageenglld:pubmed
pubmed-article:12199796pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12199796pubmed:citationSubsetIMlld:pubmed
pubmed-article:12199796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12199796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12199796pubmed:statusMEDLINElld:pubmed
pubmed-article:12199796pubmed:monthSeplld:pubmed
pubmed-article:12199796pubmed:issn0007-1048lld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:MinYoo HongYHlld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:JangJoon HoJHlld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:KimJin SeokJSlld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:LeeSeung...lld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:HahnJee...lld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:KoYun WoongYWlld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:CheongJune-Wo...lld:pubmed
pubmed-article:12199796pubmed:authorpubmed-author:MaemgHo-Young...lld:pubmed
pubmed-article:12199796pubmed:issnTypePrintlld:pubmed
pubmed-article:12199796pubmed:volume118lld:pubmed
pubmed-article:12199796pubmed:ownerNLMlld:pubmed
pubmed-article:12199796pubmed:authorsCompleteYlld:pubmed
pubmed-article:12199796pubmed:pagination1128-31lld:pubmed
pubmed-article:12199796pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:meshHeadingpubmed-meshheading:12199796...lld:pubmed
pubmed-article:12199796pubmed:year2002lld:pubmed
pubmed-article:12199796pubmed:articleTitleTreatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.lld:pubmed
pubmed-article:12199796pubmed:affiliationDepartment of Internal Medicine and BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.lld:pubmed
pubmed-article:12199796pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12199796pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12199796lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12199796lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12199796lld:pubmed